TTR and cardiac amyloidosis: Irrespective of ATTR subtype, early suspicion and prompt diagnosis of cardiac amyloidosis is key to targeting treatments and thereby improving patient outcomes; there is now evidence from randomized controlled trials that TTR directed therapies can provide benefit to subjects when treated early in the disease process [8–11]